COLLEGE STATION, Texas, Sept. 4 (TNSPer) -- Texas A&M University's College of Engineering issued the following news: By Kim Foli Ikpo It was 33 years ago when Dr. John E. Hurtado took a Greyhound bus from Fresno, California, to College Station, Texas. Following the sage advice of his professor at San Diego State University, he visited Aggieland to see if it would be a good fit for him to attend graduate school. The rest, as they say, is history. And now, more than three decades later, he's lea  more

WASHINGTON, Sept. 1 -- The Defense Nuclear Facilities Safety Board's Resident Inspector in Los Alamos National Laboratory issued the following weekly report: MEMORANDUM FOR: Christopher J. Roscetti, Technical Director FROM: D. Gutowski, Resident Inspector SUBJECT: Los Alamos Activity Report for Week Ending August 13, 2021 DNFSB Staff Activity: On Tuesday, staff members held a call with Environmental Management Field Office personnel to support a review of DOE directives in the Legacy Cleanup  more

WASHINGTON, Sept. 1 -- The Defense Nuclear Facilities Safety Board's Resident Inspector in Oak Ride National Laboratory issued the following weekly report: TO: Christopher J. Roscetti, Technical Director FROM: Matthew Duncan and Brandon Weathers, Resident Inspectors SUBJECT: Oak Ridge Activity Report for Week Ending August 13, 2021 Building 9204-2E: Operators performed a surveillance of chip dolly cylinders to check for indications of solvent leakage and found that 5 of the 16 cylinders had   more

WASHINGTON, Sept. 1 -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release: An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages   more

WASHINGTON, Sept. 1 (TNSRes) -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release on Aug. 31, 2021: An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women age  more